SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Stephens Kristin

(Last)

(First)

(Middle)

C/O SYROS PHARMACEUTICALS, INC.

35 CAMBRIDGEPARK DRIVE

(Street)

CAMBRIDGE

02140

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/08/2021

3. Issuer Name and Ticker or Trading Symbol
Syros Pharmaceuticals, Inc. [ SYRS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Development Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	45,000⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽²⁾	10/20/2025	Common Stock	20,000	6.94	D
Stock Option (right to buy)	⁽²⁾	03/30/2026	Common Stock	6,666	8.51	D
Stock Option (right to buy)	⁽²⁾	05/31/2026	Common Stock	6,666	11.66	D
Stock Option (right to buy)	⁽²⁾	09/14/2026	Common Stock	12,750	12.59	D
Stock Option (right to buy)	⁽²⁾	02/09/2027	Common Stock	38,200	10.9	D
Stock Option (right to buy)	⁽³⁾	02/15/2028	Common Stock	30,000	10.09	D
Stock Option (right to buy)	⁽⁴⁾	08/30/2028	Common Stock	7,200	12.29	D
Stock Option (right to buy)	⁽⁵⁾	02/11/2029	Common Stock	53,350	6.71	D
Stock Option (right to buy)	⁽⁶⁾	02/12/2030	Common Stock	84,000	7.54	D
Stock Option (right to buy)	⁽⁷⁾	06/10/2030	Common Stock	10,000	9.17	D
Stock Option (right to buy)	⁽⁸⁾	02/16/2031	Common Stock	94,000	11.41	D

Explanation of Responses:

1. The reporting person was granted restricted stock units, with each unit representing the right to receive one share of the issuer's common stock. These restricted stock units will vest in full on March 31, 2022.

2. This option is fully vested.

3. Option vested as to 25% of the shares on February 28, 2019 with the remaining shares vesting in equal monthly installments thereafter through February 28, 2022.

4. Option vested as to 25% of the shares on August 31, 2019 with the remaining shares vesting in equal monthly installments thereafter through August 31, 2022.

5. Option vested as to 25% of the shares on February 29, 2020 with the remaining shares vesting in equal monthly installments thereafter through February 28, 2023.

6. Option vested as to 25% of the shares on February 28, 2021 with the remaining shares vesting in equal monthly installments thereafter through February 28, 2024.

7. Option vests as to 25% of the shares on June 11, 2021 with the remaining shares vesting in equal monthly installments thereafter through June 11, 2024.

8. Option vests as to 25% of the shares on February 28, 2022 with the remaining shares vesting in equal monthly installments thereafter through February 28, 2025.

Remarks:

Exhibit 24: Power of Attorney

	/s/ Kristin Stephens	06/10/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.